A prospective study of plasma ferritin level and incident diabetes: The Atherosclerosis Risk in Communities (ARIC) Study

American Journal of Epidemiology

Volumn 165, Issue 9, 2007, Pages 1047-1054

  Jehn, Megan L ^a,b   Guallar, Eliseo ^a,c,i   Clark, Jeanne M ^a,c   Couper, David ^d   Duncan, Bruce B ^e   Ballantyne, Christie M ^f   Hoogeveen, Ron C ^f   Harris, Z Leah ^g   Pankow, James S ^h  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d IL   (United States)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g DEPARTMENT OF PATHOLOGY   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cohort studies; Diabetes mellitus, type 2; Ferritins; Incidence; Iron

Indexed keywords

FERRITIN; GLUCOSE; IRON;

COHORT ANALYSIS; DIABETES; DISEASE INCIDENCE; HEALTH RISK; METABOLISM; PROTEIN; RISK FACTOR;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNICITY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IRON BLOOD LEVEL; IRON METABOLISM; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING;

ARTERIOSCLEROSIS; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FERRITINS; HUMANS; INCIDENCE; IRON OVERLOAD; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 34247145802     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwk093     Document Type: Article

References (50)

1. Witte DL, Crosby WH, Edwards CQ, et al. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
2. Eshed I, Elis A, Lishner M. Plasma ferritin and type 2 diabetes mellitus: a critical review. Endocr Res 2001;27:91-7.
3. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002;51:2348-54.
4. Wilson JG, Lindquist JH, Grambow SC, et al. Potential role of increased iron stores in diabetes. Am J Med Sci 2003;325:332-9.
5. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 1999;22:1978-83.
6. Fernandez-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998;21:62-8.
7. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27:2422-8.
8. Chen J, Wildman RP, Hamm LL, et al. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004 Dec;27:2960-5.
9. Tuomainen TP, Nyyssonen K, Salonen R, et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. Diabetes Care 1997;20:426-8.
10. Haap M, Fritsche A, Mensing HJ, et al. Association of high serum ferritin concentration with glucose intolerance and insulin resistance in healthy people. Ann Intern Med 2003;139:869-71.
11. Salonen JT, Tuomainen TP, Nyyssonen K, et al. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ 1998;317:727.
12. Jiang R, Manson JE, Meigs JB, et al. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004;291:711-17.
13. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129:687-702.
14. Chambless LE, Folsom AR, Davis V, et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2002;155:38-47.
15. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: The Atherosclerosis Risk in Communities Study. Diabetes 2003;52:1799-805.
16. Pankow JS, Duncan BB, Schmidt MI, et al. Fasting plasma free fatty acids and risk of type 2 diabetes: The Atherosclerosis Risk in Communities Study. Diabetes Care 2004;27:77-82.
17. Lin DY. On fitting Cox's proportional hazards models to survey data. Biometrika 2000;87:37-47.
18. RTI International. SUDAAN user's manual. Release 9.0. Research Triangle Park, NC: RTI International, 2005.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
20. Niederau C, Berger M, Stremmel W, et al. Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia 1984;26:441-4.
21. Cavallo-Perin P, Pacini G, Cerutti F, et al. Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. Metabolism 1995;44:281-6.
22. Cario H, Holl RW, Debatin KM, et al. Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. Eur J Pediatr 2003;162:139-46.
23. Dmochowski K, Finegood DT, Francombe W, et al. Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 1993;77:478-83.
24. Rahier J, Loozen S, Goebbels RM, et al. The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia 1987;30:5-12.
25. Heath AL, Fairweather-Tait SJ. Health implications of iron overload: the role of diet and genotype. Nutr Rev 2003;61:45-62.
26. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27:2422-8.
27. Yokomori N, Iwasa Y, Aida K, et al. Transcriptional regulation of ferritin messenger ribonucleic acid levels by insulin in cultured rat glioma cells. Endocrinology 1991;128:1474-80.
28. Tanner LI, Lienhard GE. Insulin elicits a redistribution of transferrin receptors in 3T3-L1 adipocytes through an increase in the rate constant for receptor externalization. J Biol Chem 1987;262:8975-80.
29. Ferrannini E. Insulin resistance, iron, and the liver. Lancet 2000;355:2181-2.
30. Zelzer E, Levy Y, Kahana C, et al. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 1998;17:5085-94.
31. Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem 1992;267:18148-53.
32. Tsuji Y, Ayaki H, Whitman SP, et al. Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol 2000;20:5818-27.
33. Orino K, Lehman L, Tsuji Y, et al. Ferritin and the response to oxidative stress. Biochem J 2001;357:241-7.
34. Ponka P, Beaumont C, Richardson DR. Function and regulation of transferrin and ferritin. Semin Hematol 1998;35:35-54.
35. Pantopoulos K, Hentze MW. Nitric oxide signaling to iron-regulatory protein: direct control of ferritin mRNA translation and transferrin receptor mRNA stability in transfected fibroblasts. Proc Natl Acad Sci U S A 1995;92:1267-71.
36. Eisenstein RS. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 2000;20:627-62.
37. Tran TN, Eubanks SK, Schaffer KJ, et al. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 1997;90:4979-86.
38. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002;99:3505-16.
39. Ferroni P, Basili S, Falco A, et al. Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep 2004;6:424-31.
40. Deedwania PC. Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diab Rep 2003;3:289-92.
41. Caballero AE. Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes. Curr Diab Rep 2004;4:237-46.
42. Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 2004;28:167-72.
43. Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep 2002;2:210-15.
44. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999;117:1155-63.
45. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-18.
46. Linder MC, Schaffer KJ, Hazegh-Azam M, et al. Serum ferritin: does it differ from tissue ferritin? J Gastroenterol Hepatol 1996;11:1033-6.
47. Lee DH, Jacobs DR Jr. Serum markers of stored body iron are not appropriate markers of health effects of iron: a focus on serum ferritin. Med Hypoth 2004;62:442-5.
48. Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 1999;99:852-4.
49. Sempos CT, Looker AC. Iron status and the risk of coronary heart disease: an example of the use of nutritional epidemiology in chronic disease research. J Nutr Biochem 2001;12:170-82.
50. Moore M, Folsom AR, Barnes RW, et al. No association between serum ferritin and asymptomatic carotid atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1995;141:719-23.